U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a new federal initiative to build a comprehensive autism data platform using Medicare and Medicaid records. Designed to study the causes of autism spectrum disorder (ASD), the platform will integrate claims data, electronic health records, and data from wearable health devices, according to the Department of Health and Human Services (HHS).
The National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) will collaborate on the effort, which is part of a broader $50 million research initiative to investigate potential environmental and medical causes of autism. Kennedy stated the project aims to provide "honest answers families have waited far too long to hear," despite his controversial history promoting a debunked link between vaccines and autism.
HHS said the platform will help researchers analyze autism diagnoses, treatment outcomes, healthcare access disparities, and the financial impact on families. However, experts like Dr. Helen Tager-Flusberg of Boston University argue the focus does not directly address autism’s root causes. She also noted that an existing NIH autism database recently went offline without explanation, raising concerns about transparency.
The project has sparked privacy questions, as HHS has not confirmed whether the database will be anonymous or voluntary. Autism researcher Eric Rubenstein noted that Medicaid and Medicare data offer insights into health disparities but lack environmental exposure data, which Kennedy claims he will explore.
Autism rates have surged in recent years, with the CDC reporting 1 in 31 U.S. 8-year-olds diagnosed in 2022. While Kennedy aims to identify autism’s causes by September, scientists emphasize that autism likely stems from a complex mix of genetic and environmental factors. Critics warn against oversimplifying this ongoing scientific challenge.


U.S. Halts Visa Processing for Afghan Nationals Amid Security Concerns
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates
Minneapolis Leaders Push Back as Trump Escalates Rhetoric Against Somali Community
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Trump Administration Halts Immigration, Green Card, and Citizenship Processing for 19 Countries
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Trump Calls for Permanent Pause on Migration After National Guard Shooting Near White House
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban
National Guard Member Killed in White House-Area Shooting Sparks Terror Probe and Immigration Review
Japan Approves $117 Billion Budget to Power Stimulus and Support Growth
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 



